Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UT Southwestern tests new asthma medicine targeting vulnerable inner-city children

23.10.2006
UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma.

"Children living in inner cities are exposed to higher allergen levels and tend to have more severe asthma than children living elsewhere," said Dr. Rebecca Gruchalla, chief of allergy at UT Southwestern. "We want to see whether this new treatment can help children with allergic asthma, for which the environmental factors are more difficult to control."

Indoor allergens commonly found in inner cities, such as dust mites, cockroaches, molds and animal dander, are significant allergens that may contribute to the severity of a child's asthma. UT Southwestern, along with 10 other sites around the country, is participating in a National Institutes of Health-supported evaluation of anti-IgE therapy for children. This therapy is already being used successfully in adults and adolescents who have asthma.

"IgE antibodies are the fuel in the immune system that perpetuates the asthmatic reaction," said Dr. Gruchalla, serves as principal investigator at the Dallas site. Some people are more genetically prone to develop IgE antibodies, which are molecules produced by white blood cells in response to exposure to allergens. IgE antibodies can make asthma worse in those people who are sensitive to particular allergens.

The Inner City Anti-IgE Therapy for Asthma (ICATA) study involves about 50 children at each site. It will evaluate Xolair (omalizumab), a drug that binds to and inactivates IgE antibodies.

"Xolair 'sops up' the IgE that's there, decreases the receptors for IgE, and regulates many things that pertain to allergy and the asthmatic response," Dr. Gruchalla said.

The two-year Dallas portion of the study targets children 6 to 20 years old who reside within the Dallas Independent School District. Individuals interested in participating should call 214-648-5436 for additional requirements and information.

Participating children will receive an injection every two or four weeks and medical care for their asthma for nearly two years. Laboratory analyses of biological and environmental samples from the home also will occur during the same time period.

The $15 million study is funded through the Inner-City Asthma Consortium (ICAC), an NIH-sponsored, $55.8 million, six-year contract to investigate treatments and causes of asthma in urban children. Novartis Pharmaceuticals Corp. and Genentech, which are providing about $8 million toward the study, are also donating an additional $6 million in medication. The balance of funding will be provided by the National Institute of Allergy and Infectious Diseases.

The consortium is administered by the University of Wisconsin-Madison. Other research sites in addition to UT Southwestern are: the University of Arizona, Boston University, Children's Memorial Hospital in Chicago, Rainbow Babies and Children's Hospital in Cleveland, Children's National Medical Center in Washington, D.C., National Jewish Medical and Research Center in Denver, Johns Hopkins University, Mount Sinai School of Medicine, and St. Louis Children's Hospital.

Dr. Gruchalla has led the Dallas arm of the Inner City Asthma Consortium for four years. She is also principal investigator of an asthma screening project in Dallas schools and project director for Community Leadership in Preventing Asthma, a study evaluating links between asthma-associated morbidity and allergen levels in schools and homes.

Other UT Southwestern investigators in the ICATA study are Dr. William Neaville, assistant professor of pediatrics and internal medicine, and Dr. Vanthaya Gan, professor of pediatrics.

Russell Rian | EurekAlert!
Further information:
http://www.utsouthwestern.edu

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>